About Ultragenyx Pharmaceutical (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is developing various biologics product candidates, including Burosumab, a human monoclonal antibody that is in Phase III study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It is also developing a range of small-molecule product candidates, such as UX007, a substrate replacement therapy that completed Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome. In addition, the company is developing adeno-associated virus 8 (AAV8) gene therapy products comprising DTX301, an AAV8 for the treatment of OTC deficiency; DTX401, an AAV8 gene therapy program for the treatment of patients with GSDIa; and DTX201, a FVIII gene therapy program for the treatment of hemophilia A. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-7.23
Forward P/E Ratio-9.06
Sales & Book Value
Annual Sales$2.61 million
Price / Sales1,031.36
Price / CashN/A
Book Value$8.68 per share
Price / Book6.25
EPS (Most Recent Fiscal Year)($7.50)
Return on Equity-76.39%
Return on Assets-64.67%
Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions
What is Ultragenyx Pharmaceutical's stock symbol?
Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."
How were Ultragenyx Pharmaceutical's earnings last quarter?
Ultragenyx Pharmaceutical (NASDAQ:RARE) posted its earnings results on Tuesday, February, 20th. The biopharmaceutical company reported ($2.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.00) by $0.27. The biopharmaceutical company had revenue of $2.41 million for the quarter, compared to analyst estimates of $0.75 million. During the same quarter in the previous year, the firm earned ($1.75) EPS. View Ultragenyx Pharmaceutical's Earnings History.
When is Ultragenyx Pharmaceutical's next earnings date?
What price target have analysts set for RARE?
19 equities research analysts have issued twelve-month price targets for Ultragenyx Pharmaceutical's shares. Their predictions range from $55.00 to $83.00. On average, they expect Ultragenyx Pharmaceutical's stock price to reach $69.7647 in the next twelve months. View Analyst Ratings for Ultragenyx Pharmaceutical.
What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?
Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. " (1/30/2018)
- 2. JPMorgan Chase analysts commented, "RARE’s 3Q report this afternoon was relatively uneventful aside from a few small updates: 1) RARE now has biopsy data from 6 adult patients that are included in the FDA review of burosumab (KRN23); 2) 48 week Phase 3 data for burosumab in adults will be available by YE17; and 3) the DMTX acquisition could close as early as Nov 7 th . Additionally, the company plans on hosting an analyst day in NY on December 4 th during which they plan on sharing some additional details regarding their earlier stage pipeline." (11/5/2017)
- 3. Cowen Inc analysts commented, "We continue to see Pacira’s Exparel franchise as one of the most durable in specialty pharma and we believe that, over time, Exparel will continue to gain acceptance in the ortho community." (6/29/2017)
- 4. Canaccord Genuity analysts commented, "INSM’s Ph3 Arikayce NTM CONVERT trial data is due ~September of this year." (5/8/2017)
Who are some of Ultragenyx Pharmaceutical's key competitors?
Some companies that are related to Ultragenyx Pharmaceutical include Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Gal�pagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Array BioPharma (ARRY), Tesaro (TSRO), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD) and Ascendis Pharma (ASND).
Who are Ultragenyx Pharmaceutical's key executives?
Ultragenyx Pharmaceutical's management team includes the folowing people:
- Dr. Emil D. Kakkis, Pres, CEO & Director (Age 58)
- Ms. Shalini Sharp, Exec. VP & CFO (Age 43)
- Ms. Karah Herdman Parschauer, Exec. VP and Gen. Counsel (Age 40)
- Mr. John Richard Pinion II, Chief Quality Operations Officer and Exec. VP of Analytical Sciences & Research (Age 52)
- Dr. Jayson Donald Alexander Dallas M.D., Chief Commercial Officer and Exec. VP (Age 50)
Has Ultragenyx Pharmaceutical been receiving favorable news coverage?
News stories about RARE stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ultragenyx Pharmaceutical earned a news impact score of 0.16 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 47.19 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Ultragenyx Pharmaceutical?
Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ultragenyx Pharmaceutical's stock price today?
One share of RARE stock can currently be purchased for approximately $54.26.
How big of a company is Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical has a market capitalization of $2.69 billion and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-302,130,000.00 in net income (profit) each year or ($7.50) on an earnings per share basis. Ultragenyx Pharmaceutical employs 520 workers across the globe.
How can I contact Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]
MarketBeat Community Rating for Ultragenyx Pharmaceutical (RARE)MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target and Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
19 Wall Street analysts have issued ratings and price targets for Ultragenyx Pharmaceutical in the last 12 months. Their average twelve-month price target is $69.7647, suggesting that the stock has a possible upside of 28.57%. The high price target for RARE is $83.00 and the low price target for RARE is $55.00. There are currently 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy."
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Hold|
|Consensus Rating Score: ||2.79||2.74||2.67||2.41|
|Ratings Breakdown: ||0 Sell Rating(s)|
4 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
8 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$69.7647||$68.7647||$72.0625||$71.9375|
|Price Target Upside: ||28.57% upside||31.43% upside||46.59% upside||28.90% upside|
Ultragenyx Pharmaceutical (NASDAQ:RARE) Consensus Price Target History
Ultragenyx Pharmaceutical (NASDAQ:RARE) Analyst Ratings History
(Data available from 4/22/2016 forward)
Ultragenyx Pharmaceutical (NASDAQ:RARE) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Ultragenyx Pharmaceutical (NASDAQ RARE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 87.19%
Ultragenyx Pharmaceutical (NASDAQ RARE) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/28/2017||Emil D Kakkis||CEO||Buy||7,500||$52.52||$393,900.00||430,569|| |
|5/26/2017||Theodore Alan Huizenga||VP||Sell||480||$57.46||$27,580.80||9,366|| |
|3/9/2017||Theodore Alan Huizenga||Insider||Sell||2,500||$86.34||$215,850.00|| |
|3/2/2017||Shalini Sharp||CFO||Sell||12,000||$90.10||$1,081,200.00||67,887|| |
|2/27/2017||Shalini Sharp||CFO||Sell||12,000||$80.14||$961,680.00||63,887|| |
|12/5/2016||William Aliski||Director||Sell||6,000||$78.19||$469,140.00||65,985|| |
|11/9/2016||Shalini Sharp||CFO||Sell||24,000||$71.20||$1,708,800.00||69,387|| |
|10/19/2016||Shalini Sharp||CFO||Sell||12,000||$61.40||$736,800.00||57,387|| |
|10/14/2016||Emil D Kakkis||CEO||Sell||20,000||$63.02||$1,260,400.00||480,632|| |
|8/15/2016||Emil D Kakkis||CEO||Sell||20,000||$67.61||$1,352,200.00||493,244|| |
|7/21/2016||Sunil Agarwal||Insider||Sell||649||$52.68||$34,189.32|| |
|7/15/2016||Emil D Kakkis||CEO||Sell||20,000||$50.85||$1,017,000.00||513,597|| |
|6/20/2016||Sunil Agarwal||Insider||Sell||650||$54.16||$35,204.00|| |
|5/24/2016||Sunil Agarwal||Insider||Sell||650||$66.00||$42,900.00||7,111|| |
|5/16/2016||Emil D Kakkis||CEO||Sell||20,000||$59.95||$1,199,000.00||526,704|| |
|4/20/2016||Sunil Agarwal||Insider||Sell||649||$70.53||$45,773.97||9,216|| |
|4/15/2016||Emil D Kakkis||CEO||Sell||20,000||$70.33||$1,406,600.00||552,729|| |
|3/22/2016||Sunil Agarwal||Insider||Sell||650||$61.45||$39,942.50||9,608|| |
|2/22/2016||Sunil Agarwal||Insider||Sell||658||$63.48||$41,769.84|| |
|1/20/2016||Sunil Agarwal||insider||Sell||585||$72.83||$42,605.55||12,190|| |
|12/31/2015||Emil D. Kakkis||CEO||Sell||20,000||$114.52||$2,290,400.00||575,640|| |
|12/22/2015||Sunil Agarwal||Insider||Sell||498||$114.81||$57,175.38||13,231|| |
|12/18/2015||Theodore Alan Huizenga||insider||Sell||1,500||$110.55||$165,825.00||2,500|| |
|8/20/2015||Sunil Agarwal||insider||Sell||17,020||$111.18||$1,892,283.60||16,900|| |
|8/12/2015||Thomas Richard Kassberg||SVP||Sell||3,334||$109.70||$365,739.80|| |
|7/20/2015||Shalini Sharp||CFO||Sell||3,854||$131.95||$508,535.30|| |
|7/8/2015||Thomas Richard Kassberg||SVP||Sell||3,334||$102.12||$340,468.08|| |
|6/18/2015||Shalini Sharp||CFO||Sell||4,000||$96.08||$384,320.00|| |
|6/17/2015||Theodore Alan Huizenga||Insider||Sell||1,500||$94.80||$142,200.00|| |
|6/10/2015||Thomas Richard Kassberg||SVP||Sell||3,334||$88.19||$294,025.46|| |
|4/20/2015||Shalini Sharp||CFO||Sell||4,000||$62.23||$248,920.00|| |
|4/8/2015||Thomas Richard Kassberg||SVP||Sell||3,333||$58.02||$193,380.66|| |
|1/20/2015||Shalini Sharp||CFO||Sell||4,000||$51.24||$204,960.00|| |
|12/18/2014||Shalini Sharp||CFO||Sell||4,000||$44.82||$179,280.00|| |
|12/10/2014||Thomas Richard Kassberg||SVP||Sell||3,333||$40.22||$134,053.26|| |
|12/4/2014||William Aliski||Director||Sell||6,000||$42.16||$252,960.00|| |
|11/20/2014||Shalini Sharp||CFO||Sell||4,000||$44.07||$176,280.00|| |
|11/12/2014||Thomas Richard Kassberg||SVP||Sell||3,333||$41.85||$139,486.05|| |
|10/8/2014||Thomas Richard Kassberg||SVP||Sell||3,333||$53.26||$177,515.58|| |
|9/18/2014||Shalini Sharp||CFO||Sell||4,000||$56.00||$224,000.00|| |
|9/10/2014||Thomas Richard Kassberg||SVP||Sell||3,333||$54.82||$182,715.06|| |
|9/3/2014||Thomas Richard Kassberg||SVP||Sell||20,000||$53.91||$1,078,200.00|| |
|8/18/2014||Shalini Sharp||CFO||Sell||4,000||$53.97||$215,880.00|| |
|7/14/2014||Group Holdings (Sbs) Advis Tpg||Insider||Sell||488,820||$37.60||$18,379,632.00|| |
|1/31/2014||Fmr Llc||Insider||Buy||175,000||$21.00||$3,675,000.00|| |
|1/30/2014||Shalini Sharp||CFO||Buy||4,500||$21.00||$94,500.00|| |
|1/30/2014||Thomas Richard Kassberg||SVP||Buy||1,500||$21.00||$31,500.00|| |
|1/30/2014||William Aliski||Director||Buy||5,000||$21.00||$105,000.00|| |
Ultragenyx Pharmaceutical (NASDAQ RARE) News Headlines
Ultragenyx Pharmaceutical (NASDAQ:RARE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ultragenyx Pharmaceutical (NASDAQ:RARE) Income Statement, Balance Sheet and Cash Flow Statement
Ultragenyx Pharmaceutical (NASDAQ RARE) Stock Chart for Sunday, April, 22, 2018